During Tuesday’s current trade, ImmunoGen, Inc. (NASDAQ:IMGN)’s shares decline -1.33% to $14.84.
ImmunoGen, Inc. (IMGN) declared the first presentation of findings with the Company’s CD37-targeting ADC, IMGN529, in combination with the CD20-targeting antibody, rituximab (Rituxan®), in preclinical assessments. These data are being presented in a poster at the 13th International Conference on Malignant Lymphoma taking place in Lugano, Switzerland (abstract #P-274).
Among the findings being presented are:
- IMGN529 exhibits strong synergy with rituximab and other CD20-targeting antibodies in cell lines representative of an array of non-Hodgkin lymphoma (NHL) subtypes, counting both GCB and ABC diffuse large B-cell lymphoma (DLBCL);
- Comprising with the in vitro findings, the combination of IMGN529 and rituximab was highly active against DLBCL modelsin vivo;
- Synergy also was seen in vitroin a model representative of “double hit” lymphoma, a particularly difficult-to-treat type of DLBCL characterized by deregulation of two different genes, BCL2 (or BCL6) and MYC; and
- Both IMGN529’s antibody component and its DM1 payload contributed to its synergistic activity with rituximab.
ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates comprise IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia.
Apartment Investment and Administration Co (NYSE:AIV)‘s shares drop -1.02% to $37.66, during the current trading session Tuesday’s, hitting its highest level.
Apartment Investment and Administration Co (AIV) declared that its Board of Directors declared dividends on shares of its Class A and Z Cumulative Preferred Stock.
Dividends on shares of Class A and Z Cumulative Preferred Stock are payable on July 15, 2015, to shareholders of record on July 1, 2015.
Apartment Investment and Administration Company is a real estate investment trust. The firm engages in the acquisition, ownership, administration, and redevelopment of apartment properties. It invests in real estate markets of United States. The firm primarily invests in apartment properties. Apartment Investment and Administration Company was founded on January 10, 1994 and is headquartered in Denver, Colorado.
In an afternoon trade, Sanofi SA (ADR) (NYSE:SNY)‘s shares surge 0.86% to $51.48.
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals, Inc. declared that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the approval of the investigational therapy Praluent® (alirocumab) Injection. The Committee voted 13 to 3 (with no abstentions) that Sanofi and Regeneron had sufficiently established that the low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) lowering benefit of Praluent exceeds its risks to support approval in one or more patient populations.
The Committee’s recommendation was based on Praluent’s benefit-risk profile, following review of efficacy and safety data from more than 5,000 patients across 10 pivotal Phase 3 double-blind trials ranging from six months to two years. Clinical data from the ODYSSEY Phase 3 program show comprising, positive results in reducing LDL-C. Common adverse events that were more frequently stated in patients treated with Praluent than the control groups comprised of injection site reaction and pruritus (itching).
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
First Horizon National Corp (NYSE:FHN), during its Tuesday’s current trading session 0.76% gain and closed at $15.88.
First Tennessee Bank, a 151-year-old company with a 20-year reputation as one of the best places to work in the country, has been named a 2015 top workplace by the Tennessean. And the Tennessee-based bank is looking to fill 40 jobs in and around Nashville. First Tennessee’s parent company is First Horizon National Corp. (FHN).
First Tennessee’s most recent honor as a top workplace was determined by employee responses to a survey. The Tennessean partnered with Workplace Dynamics to find which Middle Tennessee companies are most valued by employees. First Tennessee is known for a strong corporate culture that empowers employees and its commitment to diversity and its communities.
First Horizon National Corporation operates as the bank holding company for First Tennessee Bank National Association that provides various financial services in the United States and internationally. The company offers general banking services for consumers, businesses, financial institutions, and governments. It also provides investments, financial planning, trust, asset administration, credit card, and cash administration services. In addition, the company is involved in fixed income sales and trading activities; underwriting of bank-eligible securities and other fixed-income securities eligible for underwriting by financial auxiliaries; loan sales; derivative sales; and provision of advisory services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
